An update on disease biomarkers for Hodgkin lymphoma

Melita Cirillo, Sven Borchmann

Research output: Contribution to journalReview article

1 Citation (Scopus)


Introduction: Hodgkin Lymphoma (HL) carries an overall excellent prognosis for young patients treated with multimodal therapy. Predicting an individual patient’s prognosis is currently heavily dependent on imaging modalities such as Positron Emission Tomography (PET). Areas covered: Potential biomarkers from serum, tissue, circulating nucleic acids and non-tumor derived cells have all been reported to be of prognostic relevance in HL. We review a range of these biomarkers and discuss the integration of new biomarkers into individualized patient care. Expert opinion: Better prognostic markers are needed to predict an individuals response to HL therapy. Interim PET-scan improves the ability to predict long-term treatment responders. However, it is our opinion that supplementation of PET results with additional biomarkers (including circulating tumor DNA, protein biomarkers, tissue genotyping and metabolic tumor volume) are likely to improve risk stratification for future patients with HL.

Original languageEnglish
Pages (from-to)481-488
Number of pages8
JournalExpert Review of Hematology
Issue number5
Publication statusPublished - 3 May 2020


Dive into the research topics of 'An update on disease biomarkers for Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this